§ 4.5 · Section 4 · The intake gate

How we vet candidates.

The phone screens and medical reviews that decide who is treated and who is turned away. We decline a meaningful share of inquiries by design. The first "no" is the first promise Celva makes.

The intake gates
Live
01
In
02
G·01
03
G·02
04
G·03
05
Tx
Treated
Most
Declined
A share
0
Categories of decline
Phone screen, records review, consult call.
0
Gates · in order
Each catches what the previous can't.
0
Repeating decline categories
None are personal. All are documented.
None
Deposit before sign-off
No money moves until a physician signs.

Prefer to watch?

We say no, by design.

This page is a 7-minute read. The video explains why a good clinic turns people away, who gets declined, and why that first no is the honest move. Keep scrolling for the full version.

Rather read? The full breakdown continues below

The first "no" is a feature.

The medical-tourism playbook is to say yes. Inquiry forms convert to deposits convert to treatments; the clinics that say yes the loudest are the clinics that grow the fastest. We do not run that playbook. A meaningful share of inquiries are declined before they reach a deposit, and another fraction are redirected after the consult call.

The declines fall into a small number of repeating categories. None of them are personal. All of them protect the patient from a treatment that is unlikely to help or likely to harm, and protect the practice from outcomes that would not survive honest follow-up.

Funnel 01NUMHow many make it through

The numbers, stage by stage.

For the inquiries that arrive in a typical month, the rough shape of the funnel looks like this. The proportions move a little month to month, but the shape holds.

§ Figure 4.5.1 · Inquiry → treatment · typical month

Each gate removes mass.

Blue = passes through to the next gate. Red = filtered out at this gate. How much is still in the running shows at the right.

Passes
Declined here
01
Inquiries receivedForm · phone · referral
Allin
02
Pass phone screenIndication · basic eligibility
Mostsome out
03
Pass records reviewLabs · imaging · history · physician
Mostsome out
04
Cleared at consult callDirect conversation · clinical team
Mostsome out
05
TreatedScheduling · final physician sign-off
Mostfew self-decl

A meaningful share of inquiries do not become treatments. Some are filtered at the phone screen, more at the records review, and a final group at the consult call. A small additional fraction self-decline after the consult.

Reasons 02WHYThe categories we decline

Why people are turned away.

The decline reasons cluster into a small number of categories. Knowing them in advance saves people a phone call and lets them know whether to inquire at all. Click a segment to read.

§ Figure 4.5.2 · Decline reasons · distribution among declined inquiries

Of those declined, here's why.

A share
of all inquiries · declined
Active malignancy
Active or recent cancer is declined; post-remission is reviewed individually.
01
Unmanaged infection
Active sepsis, untreated HIV/TB, hepatitis flares.
02
Indication mismatch
No plausible mechanism, or evidence doesn't support the claim.
03
Pregnancy, organ failure
Pregnancy (categorical), end-stage renal/hepatic, anticoagulation.
04
Expectation mismatch
A cure for an incurable condition, or family-pressured "anything."
05
§ Reason 01 · Most common
Active malignancy.

Patients with active or recently-treated cancer are declined for IV MSC therapy. This is caution, not a claim about your case: we will not run cell therapy alongside an active cancer. Post-remission cases are reviewed individually by our medical team.

Stages 03FLOWWhat each gate actually is

The four gates, in order.

Each gate exists because something can be learned at that point that cannot be learned later. Press play to walk through, or click any gate.

§ Figure 4.5.3 · Intake gates · what each screens for

Four gates. Each catches what the previous can't.

No deposit until Gate 04 produces a written physician sign-off.

01 / 04
Gate 01Day 0
Phone screen · 15–20 minutes.

An intake coordinator runs a structured questionnaire: indication, age, comorbidities, current medications, prior cell therapy, recent imaging, and the patient's reason for inquiring. The goal is to identify obvious declines fast: active cancer, active infection, pregnancy, indication mismatch. No clinical promises are made.

§ Indication § Age § Comorbidities § Medications § Expectation
Gate 02Day 1–7
Records review · physician-read.

Recent labs (CBC, CMP, infectious panel), imaging where relevant (provided, or performed on site at Hospital Angeles), prior specialist notes. Reviewed by a Celva physician, not a coordinator. The reviewer is looking for what the phone screen could not catch: lab abnormalities, contraindications visible only on imaging, prior treatments that change the calculus.

§ CBC / CMP § Infectious panel § Imaging § Specialist notes
Gate 03Day 7–14
Consult call · not a salesperson.

A clinical conversation, not a sales pitch: plausible benefit, expected timeline, risks, alternatives, the honest "this is what we can and cannot do." Our clinical team runs the call, and you can ask to speak with the treating physician directly. Either way, a Celva physician reads your records and signs the case in writing before any deposit.

§ Plausible benefit § Risks § Alternatives § Honest framing
Gate 04Day 14+
Final medical sign-off · in writing.

Before scheduling, the physician signs the case in writing: indication, dose, source, planned protocol, identified risks. If anything changed at the consult, the case can still be declined here. The sign-off is what unlocks scheduling; nothing scheduling-side moves until it exists.

§ Indication § Dose § Source § Risks § Signed
Matrix 04FITWhat we treat, what we don't

The conditions we say yes to.

Three columns. Not a complete list, a representative sample of how categories sort. If your condition isn't here, the phone screen is the right next step.

§ Figure 4.5.4 · Indication sorting · representative sample

Treated · Case-by-case · Declined.

Hover a column to highlight its full row of examples. The yellow middle is where the most careful conversations happen.

Treated
Osteoarthritis (knee, hip)

Established mechanism; published evidence for symptomatic improvement.

IV or local depending on joint.
Autoimmune (RA, lupus, MS)

Plausible immunomodulatory mechanism; realistic expectations.

Not a cure; symptomatic.
Post-injury / orthopedic

Local application; established orthobiologic context.

MRI required for joints.
Case-by-case
Crohn's, ulcerative colitis

Plausible mechanism, mixed published data.

Recent GI workup required.
Chronic fatigue, long COVID

Reviewed against current evidence; expectations carefully framed.

Symptom diary + prior workup.
Cognitive / neurodegenerative

Evidence remains preliminary; we are honest about that.

Never offered as a cure.
Cardiac & pulmonary

Stable, controlled disease is treatable; unstable or decompensated states are reviewed individually.

Recent cardiac workup required.
Declined
Active malignancy

Categorical decline regardless of cancer type or stage.

Post-remission reviewed individually.
Pregnancy / breastfeeding

Categorical decline; insufficient safety data in this population.

Deferral, not permanent.

The yellow column is where the most careful conversations happen. The decline column is short and definitive, no amount of consult-call charm changes those answers.

The bottom line

Not every inquiry becomes a patient.

The decline is not punitive, it is the first promise Celva makes. Four gates, five recurring decline categories, no deposit until a Celva physician signs the case. If your inquiry passes all four, it's because there is real reason to believe the treatment can help; if it doesn't, you save a trip and a deposit.

The clinics that say yes the loudest are the clinics that grow the fastest. The right question for any program isn't "will you treat me?" It's "what would make you say no?"